Acalabrutinib for treating chronic lymphocytic leukaemia – guidance (TA689)

Acalabrutinib monotherapy is recommended for previously treated CLL in adults. It is also recommended in untreated CLL in adults, only if there is a 17p deletion or TP53 mutation, or if fludarabine plus cyclophosphamide and rituximab, or bendamustine plus rituximab are unsuitable

National Institute for Health and Care Excellence